Prostate cancers are managed roughly in three steps, early localized diseases are surgically removed by radical prostatectomy or radiation therapy, metastatic diseases are mainly managed by androgen deprivation therapy (ADT), and relapsed diseases after ADT (so-called castration-resistant prostate cancers or CRPC) are treated with a novel generation of anti-AR agents, such as Abiraterone and Enzalutamide [30,33]. Here, AR is linked to prostate cancer.